Relevant bibliographies by topics / Pregnancy and safety / Journal articles

Journal articles on the topic 'Pregnancy and safety'

To see the other types of publications on this topic, follow the link: Pregnancy and safety.
Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pregnancy and safety.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yalcinkaya, E., M. Celik, B. Bugan, and UC Yuksel. "Safety concerns in pregnancy." Clinics 68, no. 4 (April 25, 2013): 577. http://dx.doi.org/10.6061/clinics/2013(04)23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Varse, Ramona Georgiana, Nicolae Gica, Radu Botezatu, Gheorghe Peltecu, and Anca Maria Panaitescu. "Hydroxychloroquine - safety in pregnancy." Romanian Journal of Rheumatology 31, no. 1 (March 31, 2022): 5–9. http://dx.doi.org/10.37897/rjr.2022.1.1.

Full text
Abstract:
Hydroxychloroquine (HCQ) is an antimalarial drug containing a 4-aminoquinoline radical, with immunomodulatory, antioxidant, anti-inflammatory and vascular protective effects, which is widely used in the treatment of various rheumatological conditions and is also compatible with pregnancy. It is well known that hydroxychloroquine crosses the placental barrier and hence it can protect against adverse perinatal outcomes, such as congenital heart block in fetuses of anti-SSA/Ro positive mothers. When it is administered at daily doses inferior or equal to 400 mg, HCQ is not associated with augmented risk of perinatal morbidity and it has also been found to prevent disease flares among pregnant women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), improving maternal outcomes and being protective toward fetal health as well. However, the concerns about its safety in pregnancy are still present because studies on the risks of perinatal defects associated with HCQ administration arise sparse and have controversial results. The purpose of the current article is to make a review of the medical literature concerning the safety of HCQ in pregnancy. For this purpose, scientific research in online medical publications such as Elsevier, PubMed, and The Lancet, was conducted.
APA, Harvard, Vancouver, ISO, and other styles
3

Newsome, Melba. "Drug safety in pregnancy." New Scientist 250, no. 3338 (June 2021): 20–21. http://dx.doi.org/10.1016/s0262-4079(21)00992-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Levi-Schaffer, Francesca, and David Mankuta. "Omalizumab safety in pregnancy." Journal of Allergy and Clinical Immunology 145, no. 2 (February 2020): 481–83. http://dx.doi.org/10.1016/j.jaci.2019.11.018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Scialli, Anthony R. "Drug safety in pregnancy." Reproductive Toxicology 5, no. 5 (January 1991): 459. http://dx.doi.org/10.1016/0890-6238(91)90013-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lam, Y. W. Francis. "Alprazolam safety in pregnancy." Brown University Psychopharmacology Update 34, no. 2 (December 27, 2022): 2–3. http://dx.doi.org/10.1002/pu.30971.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Naleway, Allison L., Bradley Crane, Stephanie A. Irving, Don Bachman, Kimberly K. Vesco, Matthew F. Daley, Darios Getahun, et al. "Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination." Therapeutic Advances in Drug Safety 12 (January 2021): 204209862110212. http://dx.doi.org/10.1177/20420986211021233.

Full text
Abstract:
Background: Identifying pregnancy episodes and accurately estimating their beginning and end dates are imperative for observational maternal vaccine safety studies using electronic health record (EHR) data. Methods: We modified the Vaccine Safety Datalink (VSD) Pregnancy Episode Algorithm (PEA) to include both the International Classification of Disease, ninth revision (ICD-9 system) and ICD-10 diagnosis codes, incorporated additional gestational age data, and validated this enhanced algorithm with manual medical record review. We also developed the new Dynamic Pregnancy Algorithm (DPA) to identify pregnancy episodes in real time. Results: Around 75% of the pregnancy episodes identified by the enhanced VSD PEA were live births, 12% were spontaneous abortions (SABs), 10% were induced abortions (IABs), and 0.4% were stillbirths (SBs). Gestational age was identified for 99% of live births, 89% of SBs, 69% of SABs, and 42% of IABs. Agreement between the PEA-assigned and abstractor-identified pregnancy outcome and outcome date was 100% for live births, but was lower for pregnancy losses. When gestational age was available in the medical record, the agreement was higher for live births (97%), but lower for pregnancy losses (75%). The DPA demonstrated strong concordance with the PEA and identified pregnancy episodes ⩾6 months prior to the outcome date for 89% of live births. Conclusion: The enhanced VSD PEA is a useful tool for identifying pregnancy episodes in EHR databases. The DPA improves the timeliness of pregnancy identification and can be used for near real-time maternal vaccine safety studies. Plain Language Summary Improving identification of pregnancies in the Vaccine Safety Datalink electronic medical record databases to allow for better and faster monitoring of vaccination safety during pregnancy Introduction: It is important to monitor of the safety of vaccines after they have been approved and licensed by the Food and Drug Administration, especially among women vaccinated during pregnancy. The Vaccine Safety Datalink (VSD) monitors vaccine safety through observational studies within large databases of electronic medical records. Since 2012, VSD researchers have used an algorithm called the Pregnancy Episode Algorithm (PEA) to identify the medical records of women who have been pregnant. Researchers then use these medical records to study whether receiving a particular vaccine is linked to any negative outcomes for the woman or her child. Methods: The goal of this study was to update and enhance the PEA to include the full set of medical record diagnostic codes [both from the older International Classification of Disease, ninth revision (ICD-9 system) and the newer ICD-10 system] and to incorporate additional sources of data about gestational age. To ensure the validity of the PEA following these enhancements, we manually reviewed medical records and compared the results with the algorithm. We also developed a new algorithm, the Dynamic Pregnancy Algorithm (DPA), to identify women earlier in pregnancy, allowing us to conduct more timely vaccine safety assessments. Results: The new version of the PEA identified 2,485,410 pregnancies in the VSD database. The enhanced algorithm more precisely estimated the beginning of pregnancies, especially those that did not result in live births, due to the new sources of gestational age data. Conclusion: Our new algorithm, the DPA, was successful at identifying pregnancies earlier in gestation than the PEA. The enhanced PEA and the new DPA will allow us to better evaluate the safety of current and future vaccinations administered during or around the time of pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Safety of antithrombotics in pregnancy." Reactions Weekly &NA;, no. 427 (November 1992): 2. http://dx.doi.org/10.2165/00128415-199204270-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Clayden, Polly. "Safety of Antiretrovirals in Pregnancy." Southern African Journal of HIV Medicine 10, no. 1 (March 23, 2009): 15. http://dx.doi.org/10.4102/sajhivmed.v10i1.311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Donner, Barbara, Viswanathan Niranjan, and Gerhard Hoffmann. "Safety of Oseltamivir in Pregnancy." Drug Safety 33, no. 8 (August 2010): 631–42. http://dx.doi.org/10.2165/11536370-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Loder, Elizabeth. "Safety of Sumatriptan in Pregnancy." CNS Drugs 17, no. 1 (2003): 1–7. http://dx.doi.org/10.2165/00023210-200317010-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Toms, David A. "Safety of US during Pregnancy." RadioGraphics 33, no. 1 (January 2013): 302–3. http://dx.doi.org/10.1148/rg.331125133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Blanche, Stéphane. "Safety of Stavudine during Pregnancy." Journal of Infectious Diseases 191, no. 9 (May 2005): 1567–68. http://dx.doi.org/10.1086/429413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Natarajan, U., A. Pym, C. McDonald, P. Velisetty, SG Edwards, P. Hay, J. Welch, A. de Ruiter, GP Taylor, and J. Anderson. "Safety of nevirapine in pregnancy." HIV Medicine 8, no. 1 (January 2007): 64–69. http://dx.doi.org/10.1111/j.1468-1293.2007.00433.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Golembesky, Amanda, Maureen Cooney, Rossen Boev, Anne-Françoise Schlit, and Jürgen W. G. Bentz. "Safety of cetirizine in pregnancy." Journal of Obstetrics and Gynaecology 38, no. 7 (March 22, 2018): 940–45. http://dx.doi.org/10.1080/01443615.2018.1441271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Bleau, Nathalie, Nicholas Czuzoj-Shulman, Andrea R. Spence, and Haim Arie Abenhaim. "Safety of splenectomy during pregnancy." Journal of Maternal-Fetal & Neonatal Medicine 30, no. 14 (September 21, 2016): 1671–75. http://dx.doi.org/10.1080/14767058.2016.1222365.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

YAMAGUCHI, Koushi, Michi HISANO, Madoka HORIYA, Noriyoshi WATANABE, Takahiko KUBO, Tatsuo KATO, and Atsuko MURASHIMA. "Influenza Vaccination Safety during Pregnancy." Kansenshogaku Zasshi 84, no. 4 (2010): 449–53. http://dx.doi.org/10.11150/kansenshogakuzasshi.84.449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Ford, Nathan, Zara Shubber, Jennifer Jao, Elaine J. Abrams, Lisa Frigati, and Lynne Mofenson. "Safety of Cotrimoxazole in Pregnancy." JAIDS Journal of Acquired Immune Deficiency Syndromes 66, no. 5 (August 2014): 512–21. http://dx.doi.org/10.1097/qai.0000000000000211.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

DPEARLMAN, M., and M. EPHILLIPS. "Safety belt use during pregnancy." Obstetrics & Gynecology 88, no. 6 (December 1996): 1026–29. http://dx.doi.org/10.1016/s0029-7844(96)00333-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Hellwig, Jennifer P. "Safety of MRI During Pregnancy." Nursing for Women's Health 20, no. 6 (December 2016): 541. http://dx.doi.org/10.1016/s1751-4851(16)30323-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Van Hees, Stijn, Stephen Raimon, Joseph Nelson Siewe Fodjo, and Robert Colebunders. "Safety of ivermectin during pregnancy." Lancet Global Health 8, no. 3 (March 2020): e338. http://dx.doi.org/10.1016/s2214-109x(19)30555-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Lum, Mark, and A. John Tsiouris. "MRI safety considerations during pregnancy." Clinical Imaging 62 (June 2020): 69–75. http://dx.doi.org/10.1016/j.clinimag.2020.02.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Lin, Kueiyu Joshua, Allen A. Mitchell, Wai-Ping Yau, Carol Louik, and Sonia Hernández-Díaz. "Safety of macrolides during pregnancy." American Journal of Obstetrics and Gynecology 208, no. 3 (March 2013): 221.e1–221.e8. http://dx.doi.org/10.1016/j.ajog.2012.12.023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Koren, G., and A. Pastuszak. "SAFETY OF DRUGS DURING PREGNANCY." Southern Medical Journal 91, no. 9 (September 1998): 887. http://dx.doi.org/10.1097/00007611-199809000-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

TAYLOR, TERESA M., MARY S. O’TOOLE, RUTH I. OHLSEN, JAMES WALTERS, and LYN S. PILOWSKY. "Safety of Quetiapine During Pregnancy." American Journal of Psychiatry 160, no. 3 (March 2003): 588—a—589. http://dx.doi.org/10.1176/appi.ajp.160.3.588-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Tham, T. C. K., J. Vandervoort, R. C. K. Wong, H. Montes, A. D. Roston, A. Slivka, A. P. Ferrari, et al. "Safety of ERCP during pregnancy." American Journal of Gastroenterology 98, no. 2 (February 2003): 308–11. http://dx.doi.org/10.1111/j.1572-0241.2003.07261.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Fox, Steven R., Navakanth Gorrepati, and Mitchell S. Cappell. "Safety of Colonoscopy during Pregnancy." American Journal of Gastroenterology 102 (September 2007): S270—S271. http://dx.doi.org/10.14309/00000434-200709002-00424.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Vladutiu, Catherine J., and Harold B. Weiss. "Motor Vehicle Safety During Pregnancy." American Journal of Lifestyle Medicine 6, no. 3 (October 13, 2011): 241–49. http://dx.doi.org/10.1177/1559827611421304.

Full text
Abstract:
Motor vehicle crashes during pregnancy are the leading cause of traumatic fetal mortality and serious maternal injury, morbidity, and mortality in the United States, injuring approximately 92 500 pregnant women each year. Little is known about the circumstances surrounding these crash events and the maternal characteristics that may increase women’s vulnerability to crash-related injuries during pregnancy. Even less is known about the effects of crashes on fetal outcomes. Crash simulation studies using female anthropomorphic test devices and computational models have been conducted to better understand the mechanisms of maternal and fetal injuries and death resulting from motor vehicle crashes. In addition, several case reports describing maternal and fetal outcomes following crashes have been published in the literature. Only a few population-based studies have explored the association between motor vehicle crashes and adverse maternal and/or fetal outcomes, and even fewer have examined the effectiveness of seat belts and/or airbags in reducing the risk of these outcomes. This article reviews what is presently known about motor vehicle crashes during pregnancy, their effects on maternal and fetal outcomes, and the role of vehicle safety devices and other safety approaches in mitigating the occurrence and severity of maternal crashes and subsequent injuries. In addition, this article suggests interventions targeted toward the prevention of crashes during pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
29

Petrek, Jeanne A. "Pregnancy safety after breast cancer." Cancer 74, S1 (January 1994): 528–31. http://dx.doi.org/10.1002/cncr.2820741342.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Krupp, P., and C. Monka. "Bromocriptine in pregnancy: Safety aspects." Klinische Wochenschrift 65, no. 17 (September 1987): 823–27. http://dx.doi.org/10.1007/bf01727477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

P., Reddi Rani, Ashwini Vishalakshi L., and Lopamudra B. John. "Myomectomy in pregnancy: feasibility and safety." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 6, no. 10 (September 23, 2017): 4204. http://dx.doi.org/10.18203/2320-1770.ijrcog20174394.

Full text
Abstract:
Prevalence of myoma in pregnancy is increasing due to advances in imaging technology. Majority are asymptomatic. Symptomatic myomas are usually large, increase in size during pregnancy and give rise to various obstetrical complications. Myomectomy during pregnancy is controversial. The management of fibroids encountered during pregnancy and caesarean section is a therapeutic dilemma. Myomectomy during pregnancy and caesarean section is discouraged traditionally due to fear of miscarriage, uncontrolled bleeding, failure to obliterate the cavity, and ending in hysterectomy. Recent literature suggests myomectomy during pregnancy and caesarean section is safe in well selected cases with experienced obstetrician in a tertiary care center.
APA, Harvard, Vancouver, ISO, and other styles
32

Alhainiah, Maha, Elaf Aljifry, Ayman Alghamdi, Lujain Alrabghi, Abdullah Alharbi, Ezdehar Alrowaithi, Fatimah Almuallem, Elaf Fakeih, Bassmah Alrowaithi, and Hassan Allam. "Safety of pregnancy in uterine fibroids." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 7, no. 8 (July 26, 2018): 2985. http://dx.doi.org/10.18203/2320-1770.ijrcog20182924.

Full text
Abstract:
Uterine fibroid is one of the most common intrauterine masses among females at the reproductive age. Pregnancy and uterine fibroids are highly correlated. Pregnancy-related hormones influence the size of uterine fibroids, and fibroids have many impacts on pregnancy. Although most if the uterine fibroids are asymptomatic during pregnancy, serious complications may occur. The main complications include abortion, premature rupture of membranes, premature labor, abruptio placentae, peripartum hemorrhage, fetal malpresentation, fetal intrauterine growth retardation, small for gestational age infants, and fetal anomalies. The main risk factors for complications are related to the fibroid number, size, volume, location, and type. Large, multiple, retroplacental, submucosal, subserosal, pedunculated, or low-lying fibroids carries the highest risk for complications during pregnancy. This review will address the prevalence of uterine fibroids during pregnancy, its effects, and complications.
APA, Harvard, Vancouver, ISO, and other styles
33

Bahat Dinur, Anat, Gideon Koren, Ilan Matok, Arnon Wiznitzer, Elia Uziel, Rafael Gorodischer, and Amalia Levy. "Fetal Safety of Macrolides." Antimicrobial Agents and Chemotherapy 57, no. 7 (May 6, 2013): 3307–11. http://dx.doi.org/10.1128/aac.01691-12.

Full text
Abstract:
ABSTRACTMacrolide antibiotics are largely used in pregnancy for different bacterial infections. Their fetal safety has been studied by several groups, yielding opposing results. In particular, there have been studies claiming an association between macrolides and cardiovascular malformations. Exposure in early infancy has been associated with pyloric stenosis and intussusception. This has led to an avoidance in prescribing macrolides to pregnant women in several Scandinavian countries. The Objectives of the present study was to investigate the fetal safety of this class of drug by linking a large administrative database of drug dispensing and pregnancy outcome in Southern Israel. A computerized database of medications dispensed from 1999 to 2009 to all women registered in the Clalit health maintenance organization in southern Israel was linked with two computerized databases containing maternal and infant hospitalization records. Also, medical pregnancy termination data were analyzed. The following confounders were controlled for: maternal age, ethnicity, maternal pregestational diabetes, parity, and the year the mother gave birth or went through medical pregnancy termination. First- and third-trimester exposures to macrolide antibiotics as a group and to individual drugs were analyzed. During the study period there were 105,492 pregnancies among Clalit women that met the inclusion criteria. Of these, 104,380 ended in live births or dead fetuses and 1,112 in abortion due to medical reasons. In the first trimester of pregnancy, 1,033 women were exposed to macrolides. There was no association between macrolides and either major malformations [odds ratio (OR), 1.08; 95% confidence interval (CI), 0.84 to 1.38)] or specific malformations, after accounting for maternal age, parity, ethnicity, prepregnancy diabetes, and year of exposure. During the third trimester of pregnancy, 959 women were exposed to macrolides. There was no association between such exposure and perinatal mortality, low birth weight, low Apgar score, or preterm delivery. Similarly, no associations were demonstrated with pyloric stenosis or intussusception. Use of macrolides in the first trimester of pregnancy is not associated with an increased risk of major malformations. Exposure in the third trimester is not likely to increase neonatal risks for pyloric stenosis or intussusception in a clinically meaningful manner.
APA, Harvard, Vancouver, ISO, and other styles
34

Sperling, Rhoda S., and Laura E. Riley. "Influenza Vaccination, Pregnancy Safety, and Risk of Early Pregnancy Loss." Obstetrics & Gynecology 131, no. 5 (May 2018): 799–802. http://dx.doi.org/10.1097/aog.0000000000002573.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Way, Cynthia M. "Safety of Newer Antidepressants in Pregnancy." Pharmacotherapy 27, no. 4 (April 2007): 546–52. http://dx.doi.org/10.1592/phco.27.4.546.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Alorainy, Ibrahim A., Fahad B. Albadr, and Abdullah H. Abujamea. "Attitude towards MRI safety during pregnancy." Annals of Saudi Medicine 26, no. 4 (July 2006): 306–9. http://dx.doi.org/10.5144/0256-4947.2006.306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Nwosu, Ozioma C., and Kathaleen Bloom. "The safety of metronidazole in pregnancy." Health Care for Women International 42, no. 4-6 (March 19, 2021): 726–38. http://dx.doi.org/10.1080/07399332.2021.1882462.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Kennedy, Debra S., and Ronald P. Batagol. "Confusion about doxylamine safety in pregnancy." Medical Journal of Australia 214, no. 6 (February 24, 2021): 286. http://dx.doi.org/10.5694/mja2.50969.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Oztav, Tugba, Mehtap Arslan, Seranur Corekcioglu, Ceyhan Oflezer, Ozge Canbek, and Erhan Kurt. "Safety of electroconvulsive therapy in pregnancy." Journal of Mood Disorders 5, no. 2 (2015): 47. http://dx.doi.org/10.5455/jmood.20140811124733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Taller, András. "Safety of gastrointestinal endoscopy during pregnancy." Orvosi Hetilap 152, no. 26 (June 2011): 1043–51. http://dx.doi.org/10.1556/oh.2011.29116.

Full text
Abstract:
There are only few data of gastrointestinal endoscopy in pregnant patients. Only 0.4% of all procedures are carried out during pregnancy. Case reports and some small retrospective studies are available. Because of physiological changes in pregnancy there might be special risks of endoscopy. There might be complaints which can be physiologic during pregnancy, but can be signs of gastrointestinal disorders, too. Therefore, indications for endoscopy are not always clear and easy. Safety of the procedures is also not well studied. Besides the risks of endoscopy, medication given to the mother, electrocoagulation and radiation exposure from fluoroscopy during endoscopic retrograde cholangiopancreatography might be harmful to the fetus. Endoscopy should only be done when indication is unquestionable and strong. Only FDA „A” and „B” category medication is allowed. Gastroscopy is necessary for bleeding and for patients with pyrosis going together with alarm signs. Nausea, vomiting, abdominal pain and fecal occult blood test positivity are not indications for endoscopy, only for gastroenterogical consultation. Sigmoidoscopy is recommended for indication of lower gastrointestinal bleeding and sigmoid or rectal mass. Only therapeutic endoscopic retrograde cholangiopancreatography should be performed. Obstructive jaundice and biliary pancreatitis need immediate endoscopic intervention. The fetus must be shielded from radiation exposure. Orv. Hetil., 2011, 152, 1043–1051.
APA, Harvard, Vancouver, ISO, and other styles
41

Jin, Jill. "Safety of Medications Used During Pregnancy." JAMA 328, no. 5 (August 2, 2022): 486. http://dx.doi.org/10.1001/jama.2022.8974.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Frost Widnes, Sofia K., and Jan Schjøtt. "Advice on Drug Safety in Pregnancy." Drug Safety 31, no. 9 (2008): 799–806. http://dx.doi.org/10.2165/00002018-200831090-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;. "Safety of theophylline during pregnancy assessed." Inpharma Weekly &NA;, no. 980 (April 1995): 21. http://dx.doi.org/10.2165/00128413-199509800-00046.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Tamma, P. D., K. A. Ault, C. del Rio, M. C. Steinhoff, N. A. Halsey, and S. B. Omer. "Safety of Influenza Vaccination During Pregnancy." Obstetric Anesthesia Digest 31, no. 1 (March 2011): 8. http://dx.doi.org/10.1097/01.aoa.0000393129.17167.3e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Khalifeh, H., C. Dolman, and L. M. Howard. "Safety of psychotropic drugs in pregnancy." BMJ 350, may13 15 (May 13, 2015): h2260. http://dx.doi.org/10.1136/bmj.h2260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Polis, Rachael Leigh, Debra Gussman, Paulina Osial, and Yen-Hong Kuo. "Safety of Yoga in Pregnancy [37]." Obstetrics & Gynecology 125 (May 2015): 21S. http://dx.doi.org/10.1097/01.aog.0000465322.80077.38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Abou-Ghannam, Gael, Ihab Usta, and Anwar Nassar. "Indomethacin in Pregnancy: Applications and Safety." American Journal of Perinatology 29, no. 03 (July 22, 2011): 175–86. http://dx.doi.org/10.1055/s-0031-1284227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Kroman, Niels, Bent Ejlertsen, Maj-Britt Jensen, and Jan Wohlfahrt. "Safety of pregnancy following breast cancer." Acta Oncologica 48, no. 3 (January 2009): 471. http://dx.doi.org/10.1080/02841860802546800.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Krozy, Ronna E., and James J. Mccolgan. "Auto Safety Pregnancy and the Newborn." Journal of Obstetric, Gynecologic & Neonatal Nursing 14, no. 1 (January 1985): 11–15. http://dx.doi.org/10.1111/j.1552-6909.1985.tb02198.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Halperin, Lawrence S., R. Joseph Olk, Gisele Soubrane, and Gabriel Coscas. "Safety of Fluorescein Angiography During Pregnancy." American Journal of Ophthalmology 109, no. 5 (May 1990): 563–66. http://dx.doi.org/10.1016/s0002-9394(14)70686-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Pregnancy and safety' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography